Our solutions span the entire lifecycle of product
development and commercialisation, and can be adapted to
suit small local trials or large global programs.
End-to-end services, operational model and technology to deliver customised solutions.
Optimising real world data to drive effective outcomes and achieve regulatory authorisation.
ICON provides its full range of clinical, consulting and commercial services across several industry sectors.
Developing transformative therapies requires a flexible approach.
Partners making a difference.
We have extensive experience in a broad range of therapeutic areas. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.
ICON has lead the development of 18 vaccines resulting in FDA/EMA approvals, including the world’s first approved vaccine for COVID-19.
ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.
BioPharma companies and Medical Devices manufacturers face
growing operational, regulatory and economic challenges. ICON
provides analysis and key insights on these challenges, with
practical advice and recommendations.
Establishing a platform for improvement
Patient focused research for better outcomes.
ICON regularly contributes thought leadership to industry
media publications and conferences, and has been recognised as
one of the world’s leading Contract Research Organisations
through a number of high-profile industry awards.
18 September 2023
26 September 2023
Our mission is to help clients accelerate the development of
drugs and devices that save lives and improve quality of life.
ICON CARES is our commitment to making a positive impact on our people, environment and our community.
Clinical Research. Evolved.
Dr Andrew Garrett contributes to this article in Pharmafocus: How COVID-19 has changed pharmacovigilance. The article explores how drug safety can be ensured while numerous vaccines and treatments come to market in record time to deal with COVID-19.